U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma

U.S. Food and Drug Administration assigned a target action date of February 20, 2021 Applications based on pivotal Phase 3 CheckMate -9ER trial, which showed OPDIVO in combination with CABOMETYX improved overall survival, doubled median progression-free survival and objective response rate, and demonstrated a manageable safety profile Results from CheckMate -9ER recently presented during a Presidential Symposium at the […]

Clinical Assessment of Risk Factors for Renal Atrophy After Percutaneous Nephrolithotomy.

BACKGROUND This study explored the risk factors for renal atrophy after percutaneous nephrolithotomy (PCNL), and provides a reference for clinical prevention of renal atrophy after PCNL. MATERIAL AND METHODS According to the inclusion and exclusion criteria, the clinical data of 816 patients who underwent PCNL in our hospital from May 2013 to February 2018 were […]

X